Based on strong and selective MYC down-regulation and cell killing activity of cancer cells in vitro, we next studied the therapeutic potential of VGN50 by examining the efficacy of cancer cell killing over toxicities to mice in a PEL xenograft model with BCBL-1 cells. The gene discussed is MYC; the disease is cancer.